涉嫌财务造假 ?*ST长药被证监会立案调查

Core Points - *ST Changyao received a notice from the China Securities Regulatory Commission (CSRC) regarding an investigation into suspected false financial reporting [1] - The company was previously known as Kangyue Technology and was listed on the Shenzhen Stock Exchange in August 2014 [1] - *ST Changyao operates primarily in the pharmaceutical manufacturing sector and has a secondary focus on photovoltaic equipment [1] Financial Performance - For the first three quarters of 2025, *ST Changyao reported revenue of 105 million yuan, representing a year-on-year increase of 4.40% [1] - The company recorded a net loss attributable to shareholders of 210 million yuan, a decline of 15.89% compared to the previous year [1] Regulatory Risks - The company indicated that if the CSRC's administrative penalties confirm facts that fall under the major illegal circumstances as per the Shenzhen Stock Exchange's rules, it may face mandatory delisting [2]